These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36828201)

  • 1. The teammate trial: Study design and rationale tacrolimus and everolimus against tacrolimus and MMF in pediatric heart transplantation using the major adverse transplant event (MATE) score.
    Almond CS; Sleeper LA; Rossano JW; Bock MJ; Pahl E; Auerbach S; Lal A; Hollander SA; Miyamoto SD; Castleberry C; Lee J; Barkoff LM; Gonzales S; Klein G; Daly KP
    Am Heart J; 2023 Jun; 260():100-112. PubMed ID: 36828201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
    Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial.
    Tönshoff B; Ettenger R; Dello Strologo L; Marks SD; Pape L; Tedesco-Silva H; Bjerre A; Christian M; Meier M; Martzloff ED; Rauer B; Ng J; Lopez P
    Am J Transplant; 2019 Mar; 19(3):811-822. PubMed ID: 30125462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
    Ciancio G; Tryphonopoulos P; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Powell RH; Ruiz P; Vianna R; Burke GW
    Transplant Proc; 2016; 48(6):2006-10. PubMed ID: 27569936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial.
    Huh KH; Lee JG; Ha J; Oh CK; Ju MK; Kim CD; Cho HR; Jung CW; Lim BJ; Kim YS;
    Nephrol Dial Transplant; 2017 Aug; 32(8):1415-1424. PubMed ID: 28810721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Mycophenolate Mofetil Associated With Tacrolimus for Kidney-pancreas and Kidney Transplantation: A Systematic Review and Meta-Analysis of Randomized Studies.
    Datrino LN; Boccuzzi ML; Silva RM; Castilho PHBT; Riva WJ; Rocha JS; Tustumi F
    Transplant Proc; 2024 Jun; 56(5):1066-1076. PubMed ID: 38853029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label randomized clinical trial to evaluate the efficacy of everolimus versus tacrolimus in triple maintenance immunosuppressive therapy for kidney transplant patients.
    Assis BPS; Lasmar MF; Fabreti-Oliveira RA; Araujo SA; Oliveira J; Wanderley DC; Nascimento E
    Braz J Med Biol Res; 2021; 54(4):e9369. PubMed ID: 33681893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up.
    Kosoku A; Iwai T; Uchida J
    Transplant Proc; 2022 Mar; 54(2):293-298. PubMed ID: 35031117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.
    Tönshoff B; Tedesco-Silva H; Ettenger R; Christian M; Bjerre A; Dello Strologo L; Marks SD; Pape L; Veldandi U; Lopez P; Cousin M; Pandey P; Meier M
    Am J Transplant; 2021 Jan; 21(1):123-137. PubMed ID: 32406111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a major adverse transplant event (MATE) score to predict late graft loss in pediatric heart transplantation.
    Almond CS; Hoen H; Rossano JW; Castleberry C; Auerbach SR; Yang L; Lal AK; Everitt MD; Fenton M; Hollander SA; Pahl E; Pruitt E; Rosenthal DN; McElhinney DB; Daly KP; Desai M;
    J Heart Lung Transplant; 2018 Apr; 37(4):441-450. PubMed ID: 28465118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil without antibody induction in cadaver vs. living donor pediatric renal transplantation.
    Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; Hasan SM; Concepcion W
    Pediatr Transplant; 2003 Apr; 7(2):137-41. PubMed ID: 12654055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF
    Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.